Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220081 | 0.93 | MAPT (0.52) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL7753041 | 0.80 | SMN1; SMN2 (0.45) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL14173702 | 0.75 | ALDH1A1 (0.47) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL7714519 | 0.75 | ALDH1A1 (0.52) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL7776804 | 0.73 | ALDH1A1 (0.45) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL321283 | 0.72 | TLR4 (0.52) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL12606807 | 0.72 | TLR4 (0.52) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL109461 | 0.70 | MEN1 (0.44) | MAPTMEN1KMT2AALDH1A1GAA | |
| Ethylene SCHEMBL10579767 | 0.69 | TLR4 (0.50) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL7127498 | 0.69 | ALDH1A1 (0.49) | MAPTMEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | MAPT 1465/4885MEN1 2195/4885KMT2A 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.